EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantification of a serum titin fragment reflects dystrophin restoration in mdx mice and disease severity in patients with dystrophinopathies

Camilla Johansson, Jessica F Boehler, Kristy J Brown, Albert Jiménez-Requena, Andreas Hober iD, Fredrik Edfors, Åsa Sivertsson, Gabriella Hober, Zaïda Koeks, Nienke M van de Velde, Mathias Uhlén, Hanna Tegel und 3 weitere

Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1457-1470

DOI: 10.1177/22143602261453984 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 20.05.2026. Verfasst von Camilla Johansson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Connectin, Dystrophin. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Association Française Contre les Myopathies, Knut and Alice Wallenberg Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased dystrophin expression in muscle has been accepted as a surrogate endpoint for accelerated approval of gene therapies within Duchenne Muscular Dystrophy (DMD). Previous studies identified an N-terminal titin fragment in urine as a biomarker suitable for monitoring disease progression and therapeutic interventions. Plasma levels of a titin fragment comprising aa 2,229–2,352 were found to negatively correlate with dystrophin expression in mdx mice treated with AAV9-CK8-μDys5 micro-dystrophin gene therapy. In this study, we sought to investigate which titin fragments can be detected in serum from patients with DMD and Becker muscular dystrophy (BMD). Using bottom-up selected reaction monitoring tandem mass spectrometry, we identified several serum peptides originating from the central region of titin. Six monospecific antibodies targeting this fragment could recognise a proteolytic titin product at 100 kDa, present in serum from DMD and BMD patients, but not healthy controls. This fragment showed a steeper age-related decline in patients with DMD compared to those with BMD. We further developed a quantitative sandwich immunoassay and showed that the concentrations of this fragment were between 130 and 2,390 pM in DMD patients and 110 and 3,970 pM in BMD patients. The same assay showed titin concentration, between 170 and 990 pM in plasma from treated mdx mice, that had a significant Pearson correlation of -0.76 ( P =1.53e−08) with (micro)dystrophin expression in quadriceps. If the negative correlation with dystrophin expression in muscle is also confirmed in DMD patients treated with micro-dystrophin therapies, this serum titin fragment may serve as a potential pharmacodynamic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneConnectinDystrophinAnimalsMice, Inbred mdxHumansMaleMiceBiomarkersSeverity of Illness IndexChildAdolescentAdultFemaleYoung Adult

Stichwörter der Autor:innen

becker muscular dystrophyduchenne muscular dystrophymicro-dystrophin therapyprotein biomarkersandwich immunoassaytitin

Substanzen

ConnectinDystrophinBiomarkers

Autor:innen und Institutionen

  • Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Solid Biosciences Inc, Charlestown, MA, USA.
  • Somite Therapeutics, Brighton, MA, USA.
  • Science for Life Laboratory, School of Chemistry, Biology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Andreas Hober

Förderung

  • NINDS NIH HHS
  • Association Française Contre les Myopathies
  • Knut and Alice Wallenberg Foundation
  • Solid Biosciences Inc.
  • National Institutes of Health
  • Netherlands Organization for Health Research and Development

Zitieren

APA

Johansson, C., Boehler, J. F., Brown, K. J., Jiménez-Requena, A., Hober, A., Edfors, F., Sivertsson, Å., Hober, G., Koeks, Z., van de Velde, N. M., Uhlén, M., Tegel, H., Niks, E. H., Spitali, P., & Al-Khalili Szigyarto, C. (2026). Quantification of a serum titin fragment reflects dystrophin restoration in mdx mice and disease severity in patients with dystrophinopathies. Journal of Neuromuscular Diseases, 13(6), 1457-1470. https://doi.org/10.1177/22143602261453984

Vancouver

Johansson C, Boehler JF, Brown KJ, Jiménez-Requena A, Hober A, Edfors F, et al. Quantification of a serum titin fragment reflects dystrophin restoration in mdx mice and disease severity in patients with dystrophinopathies. Journal of Neuromuscular Diseases. 2026;13(6):1457-1470. doi:10.1177/22143602261453984

BibTeX
@article{Johansson2026,
  author = {Johansson, Camilla and Boehler, Jessica F and Brown, Kristy J and Jiménez-Requena, Albert and Hober, Andreas and Edfors, Fredrik and Sivertsson, Åsa and Hober, Gabriella and Koeks, Zaïda and van de Velde, Nienke M and Uhlén, Mathias and Tegel, Hanna and Niks, Erik H and Spitali, Pietro and Al-Khalili Szigyarto, Cristina},
  title = {Quantification of a serum titin fragment reflects dystrophin restoration in mdx mice and disease severity in patients with dystrophinopathies},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1457--1470},
  doi = {10.1177/22143602261453984}
}
Kostenlos starten →